In patients with advanced GIST who progressed on or were intolerant to first-line treatment with imatinib, ripretinib, a switch-control TKI, showed comparable median PFS as sunitinib, suggesting that ripretinib is active as second-line therapy for GIST. Additionally, ORR for patients receiving ripretinib in the KIT...
In 50 patients with advanced EGFR exon 20-mutant NSCLC, treatment with poziotinib showed confirmed ORRs of 31% by blinded independent review, with a median PFS of 5.5 months. Preclinical studies, in silico modeling, and molecular dynamics simulations showed that the poziotinib sensitivity was highly dependent...
In patients with recurrent mismatch repair proficient (MMRP) Endometrial Cancer, treatment with talazoparib and avelumab showed 11.4 % confirmed ORR and 22.9 % PFS at 6 months. Patients with homologous recombination repair (HRR) alterations and/or a platinum-free interval (PFI) of ≥6 months were more likely...
In patients with previously untreated locally advanced or metastatic TNBC, the addition of pembrolizumab to chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine–carboplatin) resulted in significantly longer overall survival than chemotherapy alone in the CPS-10 subgroup (PD-L1 expression scores of ≥ 10). No new safety signals emerged. (Ref:...
Brentuximab vedotin plus standard chemotherapy (B+AVD group) showed a 6-year OS of 93.9% compared to standard chemotherapy (ABVD group) 89.4% in patients with previously untreated, stage III/ IV HL. Fewer patients in the B+AVD group received subsequent therapy, including transplantation, and had fewer second cancers...
The addition of capivasertib to fulvestrant showed a significant PFS benefit in the original pathway-altered and non-altered subgroups. In the pathway altered subgroup, the median OS with the combination was significantly longer than fulvestrant alone. The expanded biomarker testing suggested that capivasertib predominantly benefits patients...